Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05943886
Other study ID # HEC88473-DM-101
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date August 11, 2021
Est. completion date February 17, 2023

Study information

Verified date July 2023
Source Dongguan HEC Biopharmaceutical R&D Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single-center, randomized, double-blind, placebo-controlled, escalating single-dose and multiple-dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HEC88473 injection in healthy subjects, obese subjects and subjects with type 2 diabetes mellitus (T2DM).


Description:

This study is divided into two parts, Part A is an escalating single-dose study in healthy subjects and obese subjects, and Part B is an escalating multiple-dose study in subjects with T2DM.


Recruitment information / eligibility

Status Completed
Enrollment 164
Est. completion date February 17, 2023
Est. primary completion date February 17, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: Part A 1. Males or females, between 18 and 45 years of age, inclusive, at screening. 2. Body weight = 50 kg for males and body weight = 45 kg for females. 18=body mass index (BMI)<28 kg/m2 for nonobese subjects and 28=BMI=45 kg/m2 for obese subjects. Part B 1. Males or females, between 18 and 65 years of age, inclusive, at screening. 2. 24 kg/m2=BMI=35 kg/m2. 3. Subjects diagnosed with T2DM, newly diagnosed subjects at screening, or treated with diet and exercise alone within 3 months before screening and still have poor blood glucose control, or treated with a stable dose of metformin for = 3 months before screening. 4. 7.0%= HbA1c =10.5% at screening. Exclusion Criteria: Part A 1. Smoked more than 5 cigarettes per day within 3 months before the study. 2. Immunization with a live attenuated vaccine or coronavirus vaccination within 1 month prior to screening or planned vaccination during the course of the study. 3. Positive alcohol breath test result or positive urine drug screen. 4. Blood donation (> 300 mL) or massive blood loss (> 400 mL) within 3 months before screening. Part B 1. Have type 1 diabetes mellitus. 2. Have had =1 episode of severe hypoglycemia within 6 months before screening, or history of recurrent hypoglycemia (history of hypoglycemia more than 3 times in 3 months). 3. Have acute or chronic hepatitis, signs and symptoms of any other liver disease other than nonalcoholic fatty liver disease (NAFLD), or alanine aminotransferase (ALT) level >5 times the upper limit of the reference range at screening. 4. Have serum calcitonin =20 ng/L at screening. 5. Have a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2; or have hereditary diseases that can easily induce MTC. 6. Fasted triglycerides > 5.7 mmol/L at screening. If the patient is on lipid-lowering therapies, doses must be stable for 30 days prior to screening.

Study Design


Intervention

Drug:
HEC88473 injection
HEC88473 will be provided as a 17 mg/mL solution and will be administered by subcutaneous injection in the abdomen.
Placebo
Placebo will be administered by subcutaneous injection in the abdomen.

Locations

Country Name City State
China The First Hospital of Jilin University Changchun Jilin

Sponsors (1)

Lead Sponsor Collaborator
Dongguan HEC Biopharmaceutical R&D Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) after a single dose of HEC88473 Adverse Events (AEs) Baseline to day 15
Primary Frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) after multiple dose of HEC88473 Adverse Events (AEs) Baseline to day 43
Primary Cmax Maximum observed serum concentration of HEC88473 Predose and postdose 4?8?10?12?14?24?48?72?96?168?216?336 hours
Primary AUC Area under the serum concentration-time curve (AUC) Predose and postdose 4?8?10?12?14?24?48?72?96?168?216?336 hours
Secondary OGTT Oral glucose tolerance test Day-1, Day3 and Day 7
Secondary Change from baseline of Adiponectin at day 38 Adiponectin Baseline to day 38
Secondary Fasting lipid concentration Fasting lipid concentration Baseline to day 43
Secondary Change from baseline of HbA1c at day 38 HbA1c Baseline to day 38
Secondary Assessment of the incidence of anti drug antibodies (ADA) developed against HEC88473 after dosing anti drug antibodies (ADA) Baseline to day 43
See also
  Status Clinical Trial Phase
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2